In today's ACT Brief, we examine what patient-site relationships need most at DPHARM, how platform-based AI scales across ...

In today's ACT Brief, we examine FDA's expedited pathway for first-in-human trials, why operating model design matters more ...

Benchmarking data showed sourcing approach did not reliably predict timeline, quality, or execution performance across 133 ...

As the life sciences industry continues to evolve, the ability to effectively manage and leverage preclinical CRO ...

In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, shares what she has ...

In this Q&A, Patrick Mizer, chief technology officer at Ledger Run, discusses how payment reliability has become a ...

True lab orchestration isn't about coordinating instruments, it's about connecting scientific intent, data, and decisions ...

In today's ACT Brief, we examine what genuine patient voice requires beyond buzzwords, why AI's next bottleneck is system ...

In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, explains why the full ...

In a video interview prior to the 2026 DPHARM conference, Andrea Valente, CEO of uMotif, discussed the patient-site relationship, the role of technology in clinical trial delivery ...

Why clinical development’s next AI bottleneck is not the model, but the system around it. “An AI-enabled workflow should identify the downstream implications of a change, propose aligned updates, ...

In today's ACT Brief, we examine why black-box AI fails in clinical trials, how participant understanding drives engagement ...